Researchers at the University of Illinois Chicago (UIC) have identified an ion channel protein, KCNMB1, that acts as a molecular switch to control cancer cell stiffness. By regulating this channel, scientists can force metastatic cancer cells to become rigid, making them vulnerable to destruction by the immune system. This discovery, published in the journal Developmental Cell, offers a potential new therapeutic pathway for treating metastatic disease.
The Physics of Metastasis: Why Soft Cells Survive
Metastatic cancer cells rely on physical flexibility to escape primary tumors and spread to other organs. According to Ekrem Emrah Er, a senior author of the study and assistant professor of physiology and biophysics at the UIC College of Medicine, the outer shell of a tumor is typically rigid, yet the individual cells within are remarkably “soft and flexible.”
This softness acts as a defensive mechanism. When immune cells—specifically T cells and natural killer cells—attempt to attack, soft cancer cells simply deform rather than breaking. “If a cell is soft, it’s much harder for an immune cell to attack it and shatter it,” Er noted. The immune cells effectively bounce off the cancer cells, much like a projectile hitting a piece of jelly instead of a ceramic plate.
Targeting KCNMB1 to Harden Cancer Cells
The research team sought a way to reverse this softness, identifying the ion channel protein KCNMB1 as a critical regulator of cellular stiffness. By modulating the movement of potassium ions across cell membranes, KCNMB1 dictates how rigid a cell becomes.
Previous research in Er’s laboratory identified another protein, MRTFA, which also increases cellular stiffness. However, the team found that MRTFA is a transcription factor, making it a poor drug target due to the risk of widespread, unintended downstream effects. In contrast, KCNMB1 is an ion channel, a class of proteins already commonly targeted by existing pharmaceuticals for conditions like stroke and cardiovascular disease.
Alexa Gajda, the paper’s first author and a postdoctoral fellow at UIC, highlighted the clinical potential of this discovery. “There are already drugs that target these kinds of channels, which means there may be a clearer path toward translating these findings into therapies,” Gajda said.
Experimental Results and Future Therapeutic Outlook
In animal models of metastatic breast cancer, researchers tested a potassium-channel activator known as BMS-204352. The treatment successfully reduced distant tumor growth in the lungs by restoring the immune system’s ability to recognize and kill the malignant cells. The study found that tumors often create potassium-rich environments that soften cancer cells; the drug effectively countered this suppression.
While the team emphasizes that additional research is necessary before the approach can be tested in patients, the findings establish a “biophysical front” in the fight against cancer. By shifting the focus from purely biochemical signaling to the physical properties of cells, researchers hope to create more effective strategies to prevent metastasis.
Frequently Asked Questions
- Why are metastatic cancer cells soft?
Softness allows cancer cells to be flexible, enabling them to leak out of primary tumors and evade immune cells that would otherwise destroy them. - What is KCNMB1?
KCNMB1 is an ion channel protein that regulates the flow of potassium ions across cell membranes. It acts as a switch for cell stiffness. - Can this be used as a treatment?
The study suggests that existing ion-channel-targeting drugs could potentially be repurposed to harden cancer cells, making them easier for the immune system to eliminate.
Are you interested in the intersection of biophysics and oncology? Subscribe to our newsletter for the latest updates on cancer research and emerging therapeutic technologies.
Related reading